Tirzepatide

Tirzepatide is the world's first approved GIP/GLP-1 dual receptor agonist, administered as a once-weekly subcutaneous injection for glycemic control in type 2 diabetes and chronic weight management in obese or overweight adults.

Mechanism of Action

Tirzepatide agonizes both GIP and GLP-1 receptors: GLP-1 enhances insulin secretion and suppresses appetite, while GIP improves fat metabolism and insulin sensitivity. The dual synergy delivers weight-loss and glucose-lowering effects beyond single-agonist therapies.

Clinical Benefits

• SURPASS program: HbA1c reductions up to 2.58%
• SURMOUNT trials: average weight loss up to 22.5% at 72 weeks
• Once-weekly dosing for better adherence

Dosing Information

Prescription only. Refer to the approved package insert for dosage, contraindications and adverse reactions.